Fig. 5: Kaplan–Meier estimates of PFS according to treatment arm for patients with EGFR-WT tumors and VEGF121 and VEGF165 measurement added to either low or high concentrations of VEGF-A at baseline. | Nature Communications

Fig. 5: Kaplan–Meier estimates of PFS according to treatment arm for patients with EGFR-WT tumors and VEGF121 and VEGF165 measurement added to either low or high concentrations of VEGF-A at baseline.

From: Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC

Fig. 5

Patients with EGFR-WT tumors and VEGF121 and VEGF165 measurement added to either low (left) or high (right) concentrations of tVEGF-A (A, D), VEGF121 (B, E), or VEGF165 (C, F) defined according to the corresponding median value were examined. The survival curve for Chemo/Atezo is shown in blue, and the survival curve for Chemo/Atezo/Bev is shown in red. EGFR epidermal growth factor receptor gene, PFS progression-free survival, WT wild type, tVEGF-A total vascular endothelial growth factor–A, VEGF vascular endothelial growth factor, Chemo carboplatin-pemetrexed chemotherapy, Atezo atezolizumab, Bev bevacizumab, HR hazard ratio, CI confidence interval.

Back to article page